Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Gutin

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
Breast Cancer Research : BCR|December 6, 2014
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypesKirsten M Timms, Victor Abkevich, Elisha Hughes, et al.
The Journal of Urology|February 11, 2014
Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomyJay T Bishoff, Stephen J Freedland, Leah Gerber, et al.
Future Oncology (London, England)|June 16, 2026
Development and validation of a digital pathology artificial intelligence (DPAI)-derived risk score predicting Gleason grade group reclassification for patients who are candidates for active surveillanceBrent Mabey, Lauren H Lenz, Matthew J Schiewer, et al.
Molecular Cancer Research : MCR|May 5, 2018
Biomarker Assessment of HR Deficiency, Tumor <i>BRCA1/2</i> Mutations, and <i>CCNE1</i> Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum MonotherapyEuan A Stronach, James Paul, Kirsten M Timms, et al.
JCO Precision Oncology|July 29, 2021
Comprehensive Breast Cancer Risk Assessment for <i>CHEK2</i> and <i>ATM</i> Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick ModelShannon Gallagher, Elisha Hughes, Allison W Kurian, et al.
Psychiatry Research|December 28, 2020
Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depressionAnthony J Rothschild, Sagar V Parikh, Daniel Hain, et al.
Prostate Cancer and Prostatic Diseases|September 5, 2024
Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testingLauren Lenz, Wyatt Clegg, Diana Iliev, et al.
Breast Cancer Research and Treatment|December 25, 2017
Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancerMelinda L Telli, Jessica Hellyer, William Audeh, et al.
Clinical Genitourinary Cancer|June 12, 2026
Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate CancerTodd M Morgan, Lauren H Lenz, Ivan Henriquez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2013
Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinomaIgnacio I Wistuba, Carmen Behrens, Francesca Lombardi, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Breast Cancer Research : BCR|December 6, 2014
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypesKirsten M Timms, Victor Abkevich, Elisha Hughes, et al.
The Journal of Urology|February 11, 2014
Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomyJay T Bishoff, Stephen J Freedland, Leah Gerber, et al.
Future Oncology (London, England)|June 16, 2026
Development and validation of a digital pathology artificial intelligence (DPAI)-derived risk score predicting Gleason grade group reclassification for patients who are candidates for active surveillanceBrent Mabey, Lauren H Lenz, Matthew J Schiewer, et al.
Molecular Cancer Research : MCR|May 5, 2018
Biomarker Assessment of HR Deficiency, Tumor <i>BRCA1/2</i> Mutations, and <i>CCNE1</i> Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum MonotherapyEuan A Stronach, James Paul, Kirsten M Timms, et al.
JCO Precision Oncology|July 29, 2021
Comprehensive Breast Cancer Risk Assessment for <i>CHEK2</i> and <i>ATM</i> Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick ModelShannon Gallagher, Elisha Hughes, Allison W Kurian, et al.
Psychiatry Research|December 28, 2020
Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depressionAnthony J Rothschild, Sagar V Parikh, Daniel Hain, et al.
Prostate Cancer and Prostatic Diseases|September 5, 2024
Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testingLauren Lenz, Wyatt Clegg, Diana Iliev, et al.
Breast Cancer Research and Treatment|December 25, 2017
Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancerMelinda L Telli, Jessica Hellyer, William Audeh, et al.
Clinical Genitourinary Cancer|June 12, 2026
Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate CancerTodd M Morgan, Lauren H Lenz, Ivan Henriquez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2013
Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinomaIgnacio I Wistuba, Carmen Behrens, Francesca Lombardi, et al.
Pageof 7